钟南山院士指导研发快速检测试剂盒 采一滴血15分钟就出结果

2020-02-15 陈旭婷 央视新闻客户端

2月14日,呼吸疾病国家重点实验室对外透露,近日,在钟南山院士的指导下,实验室联合多家研究机构,最新研发出新型冠状病毒IgM抗体快速检测试剂盒,并已在实验室和临床完成初步评价。

2月14日,呼吸疾病国家重点实验室对外透露,近日,在钟南山院士的指导下,实验室联合多家研究机构,最新研发出新型冠状病毒IgM抗体快速检测试剂盒,并已在实验室和临床完成初步评价。

据介绍,仅需采取一滴血就可在15分钟内肉眼观察获得检测结果,且患者的血浆稀释500至1000倍后,仍能检测出阳性条带。该试剂盒与目前诊断所用的RT-PCR核酸检测相比,检测更加简单高效,灵敏度强和特异性高,能够有效突破现有检测技术对人员、场所的限制,缩短检测用时,实现疑似患者的快速诊断和密切接触人群的现场筛查,推动了诊断筛查的前移下移。


从左至右为一位新型冠状病毒感染者的血样稀释至1:512倍后仍可被本试剂盒检出

呼吸疾病国家重点实验室表示,这一试剂盒在湖北某医院进行了应用试验。通过对部分临床已确诊为新型冠状病毒感染阳性(但PCR核酸检测阴性的)患者血样进行复检,该试剂盒能检出相当部分(IgM)阳性,提示可与核酸检测形成互补。同时,在取自湖北、广州600多份临床样本的检测试验中,试剂盒的(IgM)阳性检出率与临床诊断结果具有高度的符合率。

据介绍,目前该试剂盒(科研用)样品已大批送至湖北省武汉市、黄冈市、大冶市等地基层卫生机构等,与核酸检测等技术联合用于检测新型冠状病毒感染的测试评估。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1991086, encodeId=a4c319910864b, content=<a href='/topic/show?id=69bd91e371a' target=_blank style='color:#2F92EE;'>#试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91737, encryptionId=69bd91e371a, topicName=试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri Jan 29 07:58:00 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992624, encodeId=589719926241c, content=<a href='/topic/show?id=b9f562561a1' target=_blank style='color:#2F92EE;'>#检测试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62561, encryptionId=b9f562561a1, topicName=检测试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Wed Mar 18 13:58:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934652, encodeId=43521934652db, content=<a href='/topic/show?id=325762560c5' target=_blank style='color:#2F92EE;'>#检测试剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62560, encryptionId=325762560c5, topicName=检测试剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu Mar 19 10:58:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300348, encodeId=ac92130034891, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Feb 16 23:58:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049179, encodeId=09ae10491e914, content=院士是学术至高点,也是大家必争之地呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Sat Feb 15 11:58:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379262, encodeId=ef4d3e926299, content=向奋斗在一线的逆行者致敬, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/15/e7fddaace9d884d73cee8d16e20a9a94.jpg, createdBy=9ef65279836, createdName=33141725_96279859, createdTime=Sat Feb 15 09:57:34 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379261, encodeId=5fb83e926113, content=好消息,厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96195231140, createdName=zilinger108, createdTime=Sat Feb 15 09:57:14 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379258, encodeId=5b063e9258fd, content=好消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94213848245, createdName=Super宝也!, createdTime=Sat Feb 15 09:22:51 CST 2020, time=2020-02-15, status=1, ipAttribution=)]
    2021-01-29 tastas
  2. [GetPortalCommentsPageByObjectIdResponse(id=1991086, encodeId=a4c319910864b, content=<a href='/topic/show?id=69bd91e371a' target=_blank style='color:#2F92EE;'>#试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91737, encryptionId=69bd91e371a, topicName=试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri Jan 29 07:58:00 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992624, encodeId=589719926241c, content=<a href='/topic/show?id=b9f562561a1' target=_blank style='color:#2F92EE;'>#检测试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62561, encryptionId=b9f562561a1, topicName=检测试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Wed Mar 18 13:58:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934652, encodeId=43521934652db, content=<a href='/topic/show?id=325762560c5' target=_blank style='color:#2F92EE;'>#检测试剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62560, encryptionId=325762560c5, topicName=检测试剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu Mar 19 10:58:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300348, encodeId=ac92130034891, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Feb 16 23:58:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049179, encodeId=09ae10491e914, content=院士是学术至高点,也是大家必争之地呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Sat Feb 15 11:58:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379262, encodeId=ef4d3e926299, content=向奋斗在一线的逆行者致敬, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/15/e7fddaace9d884d73cee8d16e20a9a94.jpg, createdBy=9ef65279836, createdName=33141725_96279859, createdTime=Sat Feb 15 09:57:34 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379261, encodeId=5fb83e926113, content=好消息,厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96195231140, createdName=zilinger108, createdTime=Sat Feb 15 09:57:14 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379258, encodeId=5b063e9258fd, content=好消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94213848245, createdName=Super宝也!, createdTime=Sat Feb 15 09:22:51 CST 2020, time=2020-02-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1991086, encodeId=a4c319910864b, content=<a href='/topic/show?id=69bd91e371a' target=_blank style='color:#2F92EE;'>#试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91737, encryptionId=69bd91e371a, topicName=试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri Jan 29 07:58:00 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992624, encodeId=589719926241c, content=<a href='/topic/show?id=b9f562561a1' target=_blank style='color:#2F92EE;'>#检测试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62561, encryptionId=b9f562561a1, topicName=检测试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Wed Mar 18 13:58:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934652, encodeId=43521934652db, content=<a href='/topic/show?id=325762560c5' target=_blank style='color:#2F92EE;'>#检测试剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62560, encryptionId=325762560c5, topicName=检测试剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu Mar 19 10:58:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300348, encodeId=ac92130034891, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Feb 16 23:58:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049179, encodeId=09ae10491e914, content=院士是学术至高点,也是大家必争之地呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Sat Feb 15 11:58:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379262, encodeId=ef4d3e926299, content=向奋斗在一线的逆行者致敬, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/15/e7fddaace9d884d73cee8d16e20a9a94.jpg, createdBy=9ef65279836, createdName=33141725_96279859, createdTime=Sat Feb 15 09:57:34 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379261, encodeId=5fb83e926113, content=好消息,厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96195231140, createdName=zilinger108, createdTime=Sat Feb 15 09:57:14 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379258, encodeId=5b063e9258fd, content=好消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94213848245, createdName=Super宝也!, createdTime=Sat Feb 15 09:22:51 CST 2020, time=2020-02-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1991086, encodeId=a4c319910864b, content=<a href='/topic/show?id=69bd91e371a' target=_blank style='color:#2F92EE;'>#试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91737, encryptionId=69bd91e371a, topicName=试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri Jan 29 07:58:00 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992624, encodeId=589719926241c, content=<a href='/topic/show?id=b9f562561a1' target=_blank style='color:#2F92EE;'>#检测试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62561, encryptionId=b9f562561a1, topicName=检测试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Wed Mar 18 13:58:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934652, encodeId=43521934652db, content=<a href='/topic/show?id=325762560c5' target=_blank style='color:#2F92EE;'>#检测试剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62560, encryptionId=325762560c5, topicName=检测试剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu Mar 19 10:58:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300348, encodeId=ac92130034891, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Feb 16 23:58:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049179, encodeId=09ae10491e914, content=院士是学术至高点,也是大家必争之地呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Sat Feb 15 11:58:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379262, encodeId=ef4d3e926299, content=向奋斗在一线的逆行者致敬, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/15/e7fddaace9d884d73cee8d16e20a9a94.jpg, createdBy=9ef65279836, createdName=33141725_96279859, createdTime=Sat Feb 15 09:57:34 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379261, encodeId=5fb83e926113, content=好消息,厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96195231140, createdName=zilinger108, createdTime=Sat Feb 15 09:57:14 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379258, encodeId=5b063e9258fd, content=好消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94213848245, createdName=Super宝也!, createdTime=Sat Feb 15 09:22:51 CST 2020, time=2020-02-15, status=1, ipAttribution=)]
    2020-02-16 lqvr
  5. [GetPortalCommentsPageByObjectIdResponse(id=1991086, encodeId=a4c319910864b, content=<a href='/topic/show?id=69bd91e371a' target=_blank style='color:#2F92EE;'>#试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91737, encryptionId=69bd91e371a, topicName=试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri Jan 29 07:58:00 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992624, encodeId=589719926241c, content=<a href='/topic/show?id=b9f562561a1' target=_blank style='color:#2F92EE;'>#检测试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62561, encryptionId=b9f562561a1, topicName=检测试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Wed Mar 18 13:58:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934652, encodeId=43521934652db, content=<a href='/topic/show?id=325762560c5' target=_blank style='color:#2F92EE;'>#检测试剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62560, encryptionId=325762560c5, topicName=检测试剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu Mar 19 10:58:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300348, encodeId=ac92130034891, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Feb 16 23:58:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049179, encodeId=09ae10491e914, content=院士是学术至高点,也是大家必争之地呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Sat Feb 15 11:58:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379262, encodeId=ef4d3e926299, content=向奋斗在一线的逆行者致敬, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/15/e7fddaace9d884d73cee8d16e20a9a94.jpg, createdBy=9ef65279836, createdName=33141725_96279859, createdTime=Sat Feb 15 09:57:34 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379261, encodeId=5fb83e926113, content=好消息,厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96195231140, createdName=zilinger108, createdTime=Sat Feb 15 09:57:14 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379258, encodeId=5b063e9258fd, content=好消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94213848245, createdName=Super宝也!, createdTime=Sat Feb 15 09:22:51 CST 2020, time=2020-02-15, status=1, ipAttribution=)]
    2020-02-15 junJUN

    院士是学术至高点,也是大家必争之地呀

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1991086, encodeId=a4c319910864b, content=<a href='/topic/show?id=69bd91e371a' target=_blank style='color:#2F92EE;'>#试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91737, encryptionId=69bd91e371a, topicName=试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri Jan 29 07:58:00 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992624, encodeId=589719926241c, content=<a href='/topic/show?id=b9f562561a1' target=_blank style='color:#2F92EE;'>#检测试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62561, encryptionId=b9f562561a1, topicName=检测试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Wed Mar 18 13:58:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934652, encodeId=43521934652db, content=<a href='/topic/show?id=325762560c5' target=_blank style='color:#2F92EE;'>#检测试剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62560, encryptionId=325762560c5, topicName=检测试剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu Mar 19 10:58:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300348, encodeId=ac92130034891, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Feb 16 23:58:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049179, encodeId=09ae10491e914, content=院士是学术至高点,也是大家必争之地呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Sat Feb 15 11:58:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379262, encodeId=ef4d3e926299, content=向奋斗在一线的逆行者致敬, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/15/e7fddaace9d884d73cee8d16e20a9a94.jpg, createdBy=9ef65279836, createdName=33141725_96279859, createdTime=Sat Feb 15 09:57:34 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379261, encodeId=5fb83e926113, content=好消息,厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96195231140, createdName=zilinger108, createdTime=Sat Feb 15 09:57:14 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379258, encodeId=5b063e9258fd, content=好消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94213848245, createdName=Super宝也!, createdTime=Sat Feb 15 09:22:51 CST 2020, time=2020-02-15, status=1, ipAttribution=)]
    2020-02-15 33141725_96279859

    向奋斗在一线的逆行者致敬

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1991086, encodeId=a4c319910864b, content=<a href='/topic/show?id=69bd91e371a' target=_blank style='color:#2F92EE;'>#试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91737, encryptionId=69bd91e371a, topicName=试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri Jan 29 07:58:00 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992624, encodeId=589719926241c, content=<a href='/topic/show?id=b9f562561a1' target=_blank style='color:#2F92EE;'>#检测试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62561, encryptionId=b9f562561a1, topicName=检测试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Wed Mar 18 13:58:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934652, encodeId=43521934652db, content=<a href='/topic/show?id=325762560c5' target=_blank style='color:#2F92EE;'>#检测试剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62560, encryptionId=325762560c5, topicName=检测试剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu Mar 19 10:58:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300348, encodeId=ac92130034891, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Feb 16 23:58:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049179, encodeId=09ae10491e914, content=院士是学术至高点,也是大家必争之地呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Sat Feb 15 11:58:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379262, encodeId=ef4d3e926299, content=向奋斗在一线的逆行者致敬, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/15/e7fddaace9d884d73cee8d16e20a9a94.jpg, createdBy=9ef65279836, createdName=33141725_96279859, createdTime=Sat Feb 15 09:57:34 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379261, encodeId=5fb83e926113, content=好消息,厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96195231140, createdName=zilinger108, createdTime=Sat Feb 15 09:57:14 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379258, encodeId=5b063e9258fd, content=好消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94213848245, createdName=Super宝也!, createdTime=Sat Feb 15 09:22:51 CST 2020, time=2020-02-15, status=1, ipAttribution=)]
    2020-02-15 zilinger108

    好消息,厉害

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1991086, encodeId=a4c319910864b, content=<a href='/topic/show?id=69bd91e371a' target=_blank style='color:#2F92EE;'>#试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91737, encryptionId=69bd91e371a, topicName=试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri Jan 29 07:58:00 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992624, encodeId=589719926241c, content=<a href='/topic/show?id=b9f562561a1' target=_blank style='color:#2F92EE;'>#检测试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62561, encryptionId=b9f562561a1, topicName=检测试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Wed Mar 18 13:58:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934652, encodeId=43521934652db, content=<a href='/topic/show?id=325762560c5' target=_blank style='color:#2F92EE;'>#检测试剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62560, encryptionId=325762560c5, topicName=检测试剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu Mar 19 10:58:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300348, encodeId=ac92130034891, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Feb 16 23:58:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049179, encodeId=09ae10491e914, content=院士是学术至高点,也是大家必争之地呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Sat Feb 15 11:58:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379262, encodeId=ef4d3e926299, content=向奋斗在一线的逆行者致敬, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/15/e7fddaace9d884d73cee8d16e20a9a94.jpg, createdBy=9ef65279836, createdName=33141725_96279859, createdTime=Sat Feb 15 09:57:34 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379261, encodeId=5fb83e926113, content=好消息,厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96195231140, createdName=zilinger108, createdTime=Sat Feb 15 09:57:14 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379258, encodeId=5b063e9258fd, content=好消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94213848245, createdName=Super宝也!, createdTime=Sat Feb 15 09:22:51 CST 2020, time=2020-02-15, status=1, ipAttribution=)]
    2020-02-15 Super宝也!

    好消息!

    0

相关资讯

钟南山多项成果将落地 拟建10亿疫苗产业基地

钟南山院士曾在多个场合呼吁,要提高科研成果的转化率,如今,他的这一心愿得到实现。5月15日,由广东省南山医学发展基金会等单位联合举办的“广州医科大学钟南山团队产学研工作汇报交流会”在广州举行,交流会现场签约了一系列产学研项目,这也意味着,钟南山团队多年来的系列研究成果将“落地”成实实在在的产品,最终惠及更多居民。记者留意到,这些签约项目覆盖医疗、健康、传染病防控等多个方面,包括“10 亿级呼吸

粪口会传播新型冠状病毒吗?钟南山回应:有可能,要高度警惕

南方PLUS客户端2月2日消息,新型冠状病毒会通过粪口传播吗?最近全国确诊病例人数激增,是否说明疫情更加严重?返工潮马上来临,广东应如何防范?2月2日,南方日报、南方+记者采访到了钟南山院士,他回应了这些问题。记者:新型冠状病毒是否会通过粪口传播?应该注意什么?钟南山:新型冠状病毒有可能通过粪口传播。现在这个问题应该非常重视,因为在粪便里发现病毒,粪便是否传染病毒值得高度警惕。在湖北、江西有些地方

钟南山院士:医改多年,公立医院公益性仍未解决

定期出门诊专看疑难杂症,全力攻克“沉默的杀手”——慢性阻塞性肺疾病,主持国家呼吸系统疾病临床医学研究中心,建设大规模数据库,开发效优价廉的药物……

病例还会不会大规模增加——与钟南山面对面话疫情防控

眼下,不断变化的数字、态势严峻的疫情,牵动着千万颗心。关于病毒从何而来、什么症状该去医院、疫情高峰何时到来…… 面对各种各样的疑问与忧虑,新华社记者 28 日专访了中国工程院院士、国家呼吸系统疾病临床医学研究中心主任、高级别专家组组长钟南山。

钟南山:新型冠状病毒肺炎是肯定存在人传人

钟南山:根据目前的资料,新型冠状病毒肺炎是肯定的人传人,在广东有2个病例,没去过武汉,但家人去了武汉后染上了新型冠状病毒肺炎,现在可以说,肯定的,有人传人现象。针对如何预防新型冠状病毒,钟南山提醒:1.近期尽量避免前往武汉; 2.如果有发热等不适症状需要立即到医院查看; 3.随时佩戴口罩,但不一定必须是N95口罩。

钟南山:我相信新型冠状病毒不会持续SARS那么长时间

眼下,不断变化的数字、态势严峻的疫情,牵动着千万颗心。关于病毒从何而来、什么症状该去医院、疫情高峰何时到来……面对各种各样的疑问与忧虑,新华社记者28日专访了中国工程院院士、国家呼吸系统疾病临床医学研究中心主任、高级别专家组组长钟南山。疫情研判:还是局部大爆发问:从仅湖北武汉一地发现,截至目前30个省份报告感染确诊病例,您对新型冠状病毒感染的肺炎疫情走势如何判断?它是一个多点局部爆发,还是一个